Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019

STRASBOURG, France–(BUSINESS WIRE)–

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapies announced that the
Combined General Meeting (ordinary and extraordinary sessions) of
Transgene’s shareholders will be held on May 22, 2019, at 10 a.m. at the
Company’s registered office (400, boulevard Gonthier d’Andernach, 67400
Illkirch-Graffenstaden, France).

The notice of meeting, comprising the agenda and the draft resolutions
was published in the Bulletin des Annonces Légales Obligatoires
(BALO) n° 38 of March 29, 2019.

These notices include information on how to attend and vote at the
General Meeting.